Prostatectomía radical robot-asistida con preservación del espacio de Retzius: resultados perioperatorios y de continencia inmediata en una serie inicial / Retzius-sparing robot-assisted radical prostatectomy: Perioperative and immediate continence outcomes of an initial series

OBJETIVO: Los objetivos de este trabajo son presentar los resultados perioperatorios, de continencia inmediata y oncológicos iniciales en una serie de 25 pacientes con cáncer de próstata tratados con prostatectomía radical robot-asistida con preservación del espacio de Retzius. MATERIAL Y MÉTODOS: Analizamos retrospectivamente una serie de 25 pacientes tratados con prostatectomía radical robótica con preservación del espacio de Retzius por cáncer de próstata cT1-T2b entre 2018-2019. Se describen las 5 etapas de la cirugía. Efectuamos una estadística descriptiva de nuestra serie inicial y sus resultados en términos de continencia inmediata, definida como el uso de 0 compresas/pañales o 1 por seguridad/24 horas en la primera semana tras retirada de la sonda. RESULTADOS: Mediana de seguimiento, 6 meses (3-18). Mediana de PSA, 6,1 ng/ml (4-14,3). Todas las cirugías se realizan por vía posterior e intrafascial con preservación neurovascular bilateral en el 84% de los casos. El 28% tienen un margen quirúrgico afectado siendo el ápex la zona de afectación más frecuente. Complicaciones quirúrgicas: 1 (4%) paciente requirió transfusión de hemoderivados en el postoperatorio inmediato. Mediana de estancia hospitalaria 48 horas. Resultados funcionales: el 80% tiene continencia inmediata. El 80% de los continentes no requiere el uso de ningún pañal/compresa de seguridad. Resultados oncológicos: el 84% están libres de progresión bioquímica con una mediana de seguimiento de 6 meses. CONCLUSIONES: Los resultados funcionales iniciales en términos de continencia inmediata son muy satisfactorios en pacientes intervenidos de prostatectomía radical robótica con preservación del espacio de Retzius sin impacto negativo en el pronóstico

OBJECTIVE: The objective of this work is to present initial perioperative, immediate continence and oncological results in a series of 25 prostate cancer patients treated with Retzius-sparing robot-assisted radical prostatectomy. MATERIAL AND METHODS: We retrospectively analyzed a series of 25 patients treated with Retzius-sparing robot-assisted radical prostatectomy for cT1-T2b prostate cancer between 2018-2019. The 5 stages of surgery are described. We make a descriptive statistic of our initial series and its outcomes in terms of immediate continence, defined as the use of 0 pad/diapers or 1 safety pad/diaper every 24 hours, one week after catheter removal. RESULTS: Median follow-up, 6 months (3-18). Median PSA, 6.1 ng/ml (4-14.3). All surgeries were performed through a posterior intrafascial approach, and bilateral nerve-sparing was carried out in 84% of the cases. Affected surgical margins were present in 28%, being the apex the most frequent site of affectation. Surgical complications: 1 (4%) patient required transfusion of blood products in the immediate postoperative period. Mean hospital stay was 48 hours. Functional outcomes: 80% of the patients present immediate continence. 80% of continent patients do not require the use of any safety pads/diapers. Oncological outcomes: 84% are free of biochemical-progression in a median follow-up of 6 months. CONCLUSIONS: Initial functional results in terms of immediate continence are very satisfactory in patients who have undergone Retzius-sparing robot-assisted radical prostatectomy without negative impact on prognosis

Retzius-sparing robot-assisted radical prostatectomy: Perioperative and immediate continence outcomes of an initial series. / Prostatectomía radical robot-asistida con preservación del espacio de Retzius: resultados perioperatorios y de continencia inmediata en una serie inicial.

OBJECTIVE: The objective of this work is to present initial perioperative, immediate continence and oncological results in a series of 25 prostate cancer patients treated with Retzius-sparing robot-assisted radical prostatectomy. MATERIAL AND METHODS: We retrospectively analyzed a series of 25 patients treated with Retzius-sparing robot-assisted radical prostatectomy for cT1-T2b prostate cancer between 2018-2019. The 5 stages of surgery are described. We make a descriptive statistic of our initial series and its outcomes in terms of immediate continence, defined as the use of 0 pad/diapers or 1 safety pad/diaper every 24 hours, one week after catheter removal. RESULTS: Median follow-up, 6 months (3-18). Median PSA, 6.1 ng/ml (4-14.3). All surgeries were performed through a posterior intrafascial approach, and bilateral nerve-sparing was carried out in 84% of the cases. Affected surgical margins were present in 28%, being the apex the most frequent site of affectation. Surgical complications: 1 (4%) patient required transfusion of blood products in the immediate postoperative period. Mean hospital stay was 48 hours. Functional outcomes: 80% of the patients present immediate continence. 80% of continent patients do not require the use of any safety pads/diapers. Oncological outcomes: 84% are free of biochemical-progression in a median follow-up of 6 months. CONCLUSIONS: Initial functional results in terms of immediate continence are very satisfactory in patients who have undergone Retzius-sparing robot-assisted radical prostatectomy without negative impact on prognosis.

[Synchronous primary urologic triple neoplasia. Report of a new case and review of the literature]. / Triple neoplasia urológica primaria sincrónica. Aportación de un nuevo caso y revisión de la literatura.

Herein we present the case of a patient who went to the emergency department complaining of haematuria. With a conservative management, the radiologic and endoscopic studies show a bladder tumour and an incidental left renal mass. After several radical procedures, the last a cystoprostatectomy, it was shown that the patient had a new tumour inside his prostate gland. We comment the surgical procedures, the clinical evolution and the five years follow-up. We review the few cases described in the literature.

Triple neoplasia urológica primaria sincrónica. Aportación de un nuevo caso y revision de la literatura / Triple synchronous urologic neoplasm. Cse report and review of literature

Presentamos el caso clínico de un paciente que acudió al Servicio de Urgencias por presentar hematuria. En tratamiento conservador, los estudios radiológicos y endoscópicos pusieron de manifiesto la existencia de un tumor vesical y una masa renal izquierda incidental. Tras varias intervenciones quirúrgicas, la última, una cistoprostatectomía radical, se constató también la existencia de un nuevo tumor en el interior de la próstata. Se comentan los procedimientos quirúrgicos, la evolución clínica y el seguimiento a cinco años. Se revisan los escasos casos descritos en la literatura (AU)

No disponible

[Double J ureteral catheter. Clinical complications]. / El catéter ureteral doble J. Complicaciones clínicas.

OBJECTIVE: To analyze the clinical complications of double-J ureteral catheters. METHODS: The most relevant studies published in the literature since the self-retaining indwelling catheter was first described in 1967 are reviewed. RESULTS: The experience and results reported in the most relevant studies are presented. CONCLUSIONS: The double-J ureteral stent has become an integral part of the urological armamentarium. It allows good urinary drainage from the kidney to the bladder and is generally safe and well-tolerated. However, different complications may occur with short- or long-term use of indwelling stents. These complications vary from minor side effects such as hematuria, dysuria, frequency, flank and suprapubic pain, to major complications such as vesico-ureteric reflux, stent migration, encrustation, urinary infection, stent fracture, necrosis and ureteral fistula. Most of these complications require removal of the catheter.

[PSA and PSAD study in patients with renal dysfunction]. / Estudio de PSA y PSAD en pacientes con disfunción renal.

This study analyzes the changes in serum and urinary PSA values in 28 subjects; 13 with creatinine clearance under 75 ml/mn and 15 with creatinine clearance over 75 ml/mn. Both groups were compared for prostate size, measured by transrectal ultrasound, prostate weight, serum PSA (SPSA), 24h urine PSA (PSAO), PSA clearance (PSACl), serum creatinine (SCr), creatinine clearance (CrCl), PSA density (PSAD), PSA/creatinine ratio (PSA/Cr) and PSACl/CrCl ratio. Mean values of SPSA and PSAO were 4.5 +/- 0.8 and 222 +/- 29.7 ng/ml respectively, values for SCr, CrCl and PSACl averaging 1.62 +/- 0.2 mgr/dl, 71.6 +/- 6.5 ml/mn and 150.5 +/) 32.9 ml/mn. Median prostate size was 32.6 +/- 3.9 cc, with weights of 40.3 +/- 4.9 g and mean PSA density (PSAD) 0.13 +/- 0.02. The results of the homogeneity study showed that there are no significant differences between both groups with regard to the variables considered in the study. SPSA values were higher in patients with CrCl < 75; 3.4 vs 5.7, but not significantly. There are no significant differences between PSAO and PSACl values for both groups, even though PSAO levels were higher in patients with CrCl < 75 ml/min (p = 0.1). PSAD values for patients with CrCl > 75 ml/mn were lower than those for patients with CrCl < 75 ml/mn; 0.09 vs 0.17 (p = 0.08). In the entire sample, PSAD levels showed correlation with SPSA and PSA/Cr values; R = 0.63 (P = 0.0003) and r = 0.5 (p = 0.009) respectively. Also, they were significantly but inversely correlated with PSACl levels; r = - 0.5 (p = 0.006) and PSACl/CrCl; r = - 0.048 (p = 0.01). No correlation was seen between PSAD values and the following parameters; PSAO (p = 0.7), SCr (p = 0.5) and CrCl (p = 0.27). When the group of patients with CrCl < 75 ml/mn is considered, PSAD values are correlated exclusively with PSACl values; r = - 0.69 (p = 0.008) and PSACl/CrCl; r = 0.68 (p = 0.009). Our data appear to indicate that there is a certain relationship between PSAD and the renal function although the physiopathological mechanism responsible for that is unknown. Nevertheless, considering the sample size, more comprehensive studies will be necessary to obtain more convincing results.

Microparticle immunoenzymatic assay for detection of prostate specific antigen: characterization of the technique and comparative analysis with a monoclonal immunoradiometric assay.

Microparticle immunoenzymatic assay (MEIA) is a new, ultrasensitive technique recently introduced for detection of prostatic specific antigen (PSA). It is easily performed, totally automated, and cheaper and faster than radioimmunometric techniques. In this study, the levels of PSA in 194 males with urologic problems and healthy males, recorded by microparticle monoclonal ultrasensitive enzymoimmunoassay (MEIA) and immunoradiometric assay (IRMA), are comparatively evaluated. Variables recorded were age of patient, size and weight of the prostate, and PSA levels analyzed by the MEIA (MEIA-PSA) and IRMA (ELSA-PSA) techniques. Different determinations of PSA were performed in order to calculate the intra- and interassay variation coefficient for the MEIA-PSA assay. Means of prostatic length, width, and depth, recorded by ultrasonography, were 28.3, 35.8, and 31.4 mm, respectively, with a mean prostatic size of 19 ml and a mean prostatic weight of 23.9 g. Mean IRMA-PSA was 4.53 ng/ml and mean MEIA-PSA was 2.04 ng/ml. The difference between them was 2.49, and the ratio IRMA-PSA:MEIA-PSA was 3.17. Interassay and intraassay variation coefficients for MEIA-PSA were 6.58 and 9.96%, respectively. MEIA-PSA values correlated linearly with the age of the patients (r = 0.65, p = 0.0001), size of the prostate (r = 0.71, p = 0.0001), weight of the prostate (r = 0.71, p = 0.0001), and the value of IRMA-PSA (r = 0.80, p = 0.0001). Paired t tests showed that the values of PSA measured by MEIA and IRMA are statistically different (p = 0.0001), with independence of the level of PSA considered.

[A comparative analysis of monoclonal assays for the determination of PSA: radioimmunometric assay (ELSA) vs microparticle immunoenzyme assay (MEIA)]. / Análisis comparativo de dos ensayos monoclonales para la determinación de PSA: ensayo radioinmunométrico (ELSA) vs ensayo inmunoenzimático de micropartículas (MEIA).

Comparative analysis of PSA values measured by MEIA and ELSA techniques in a group of 70 unselected patients. A good correlation was observed between PSA levels determined by ELSA-PSA immunoradiometric techniques and those obtained by MEIA-PSA (r = 0.93, p < 0.00001). However, ELSA-PSA values have been 1.73 +/- 0.1 times higher than those by MEIA-PSA. A mean-paired comparison indicates that PSA mean levels (0.48 +/- 0.07 and 0.29 +/- 0.05 for ELSA and MEIA, respectively) are significantly different and define two groups of nonhomogeneous values (p < 0.0001). The same results are obtained when patients with PSA values higher and lower than 4 ng/ml are analyzed separately. For patients with PSA lower than 1 ng/ml, the difference between mean ELSA-PSA and MEIA-PSA values disappears; 0.74 +/- 0.08 vs 0.62 +/- 0.05, respectively (p > 0.1). In this group, the results from both assays are statistically consistent. When considering the group of patients with PSA < 1 ng/ml, no difference between both techniques becomes apparent, which seems to indicate the absence of differences in sensitivity between both techniques when considering low levels of serum PSA. Nevertheless, it is clear that the results from these techniques can not overlap and are not comparable and so, to all practical effects, it is recommended that follow-up of any particular patient is made always with the same technique and even at the same laboratory.

Multivariate analysis of progression in superficial bladder cancer.

A total of 217 patients with superficial bladder cancer (SBC) category Ta-T1 were retrospectively analysed for tumour progression and prognostic factors; 46% of patients presented with recurrences, 13% with increasing grades of anaplasia and 12% with progression in tumour category. The mean annual index of recurrences was 0.7 +/- 0.1; 4% of patients died from tumour progression and the overall 5-year survival rate was 88% +/- 5.3. Factors that influenced progression significantly were peritumoural dysplasia, inflammatory infiltrate, residual tumour following transurethral resections, increasing grade of anaplasia and index of recurrences > 0.7. Multivariate statistical analysis revealed that only tumour category and increasing grade of anaplasia had significant prognostic value. Increasing grade of anaplasia predicts the likelihood of tumour progression with a 91% global predictive capacity. Thirty percent of patients with tumour progression did not have an increasing grade of anaplasia. Among these 87% were Ta, 50% were GI and the mean index of recurrences was 0.9. All were conservatively treated and 87% are alive. Among the patients with an increasing grade of anaplasia and tumour progression the mean index of recurrences was 1.7; 67% developed muscle infiltrating cancer and 7% metastatic spread without local progression; 64% of these patients died from cancer. An increasing grade of anaplasia affects prognosis. It defines patients with a high risk of tumour progression and tumour-related death, especially those with T1 bladder cancer.

[Retroperitoneal ganglioneuroma: an infrequent tumor]. / Ganglioneuroma retroperitoneal: un tumor infrecuente.

Presentation of 2 cases of retroperitoneal ganglioneuroma (paravertebral and adrenal, respectively), accidentally diagnosed during ultrasound study. In none of these 2 cases diagnosis by thin-needle puncture-aspiration was possible, therefore, surgical exeresis of the lesion was performed. When diagnosis is made prior to surgery, management can be conservative with close follow-up, unless neuroblastoma is identified or there is other disease-derived pathologies present.

[Pure squamous carcinoma of the ureter. Review of a case]. / Carcinoma escamoso puro de uréter. Revisión de un caso.

We report a case of squamous cell carcinoma of the ureter with periureteral infiltration. Three years following radical surgery, no evidence of tumor progression has been observed. Only 1% to 1.6% of urothelial tumors of the upper urinary tract are purely squamous cell tumors. This tumor type carries a poor prognosis. Currently, the best results can be achieved by early diagnosis and radical surgery.

[Tumor thrombosis in inferior vena cava: diagnostic imaging and therapeutic approximation]. / Trombosis tumoral en vena cava inferior (TTVCI): diagnóstico por imagen y aproximación terapéutica.

Review of our experience in the diagnosis and treatment of 44 patients with inferior vena cava tumoral thrombosis (IVCTT), associated or not to other neoplastic processes: 34 hypernephroma, 2 cava leiomyosarcoma, 1 paratesticular rhabdomyosarcoma and 1 biphasic synovial sarcoma. Twenty-five patients with hypernephroma and tumor thrombi in the ipsilateral renal vein only were excluded from the analysis since this fact did not change the usual therapeutic approach. In the 19 remaining patients, concomitantly to the primary tumour exeresis a thrombectomy was performed, using cavotomy with proximal and distal clamping in 11 patients and cardiopulmonary by-pass, deep hypothermia and cardiocirculatory arrest in 8 patients. The paper analyzes the radiological investigations performed in order to reach a IVCTT diagnosis, and reviews the related literature.

[Vascular complications in 237 recipients of renal transplant from cadaver]. / Complicaciones vasculares en 237 receptores de trasplante renal de cadáver.

Between July 1976 and June 1990, 244 transplantations were performed. Of the 237 patients monitored, 13 (5.4%) had vascular complications: 10 (77%) renal artery stenosis, 1 (7.7%) primitive iliac artery stenosis, 1(7.7%) renal artery thrombosis, 1 (7.7%) renal vein thrombosis. Six patients underwent surgery (Angioplasty was performed in three patients, re-anastomosis to the common iliac artery in one, by-pass of saphenous vein in another one, while in the last one it was tried a release of the vascular pediculus). Management with drugs was possible in one case. At present, 11 of the 13 patients are still alive and three of the grafts remain functional after a mean follow-up time of 83 months. According to a univariate study, the influential factors in the development of vascular complications are, the identity of Locus A, the type of extraction in Locus B, the length of cold ischaemia, the type of vascular anastomosis and the number of previous rejections. The factors with maximal influence in the development of complications are the type of vascular suture (with or without patch) and the number of previous rejections (according to a study of log regression models). The study demonstrates the significant influence vascular complications have on the graft's durability (p = 0.005).

[Kidney pelvis tumor in ectopic kidney. Report of a case]. / Tumor de pelvis renal en riñón ectópico. A propósito de un caso.

A case of urothelial carcinoma in pelvic ectopic kidney is described. The low incidence of both pathologies and their rare association justifies the description.

[Infiltrating bladder carcinoma with metastatic lymph node involvement: radical treatment and survival]. / Carcinoma vesical infiltrante con afectación ganglionar metastásica: tratamiento radical y supervivencia.

Presentation of the results obtained from the study of 64 patients with T2-4 stage vesical carcinoma, treated with radical cystectomy, local lymphadenectomy, with and without complementary radiotherapy, with and without neoadjuvant chemotherapy. The univariate study of 19/64 patients with microscopic nodular disease revealed a significant relationship with the pathological stage but not with the clinical stage. The multivariate study demonstrated that the most relevant prognostic factors are a decrease in tumoral stage (P) and the presence of vascular and/or lymphatic involvement in the TUR-biopsy. The analysis of survival confirms the poor prognosis of patients with metastatic nodular involvement, in spite of the association of pelvic radiotherapy or neoadjuvant chemotherapy to the treatment.

[Tumors of the upper urothelium and cyclophosphamide: presentation of a case and review of the literature]. / Tumores de urotelio superior y ciclofosfamida: presentación de un caso y revisión de la literatura.

We report a case of upper urothelial tumor in a patient who had previously received prolonged cyclophosphamide therapy for Waldeström's macroglobulinemia. Although bladder tumors in cyclophosphamide-treated patients are relatively frequent, upper urothelial tumors are rare. Only 5 cases of this latter tumor type have been reported as of 1987. The literature on this disease entity is reviewed. Patients who have received prolonged therapy with cyclophosphamide or similar drugs must be followed very closely.

[Paratesticular rhabdomyosarcoma with intracaval neoplastic involvement: presentation of a case and review of the literature]. / Rabdomiosarcoma paratesticular con afectación tumoral intracava: presentación de un caso y revisión de la literatura.

One case of paratesticular embryonal rhabdomyosarcoma (RMS), affected during its evolution by a tumoral thrombus in the inferior vena cava. This unusual association forced the use of a cardiopulmonary by-pass, profound hypothermia and circulatory arrest, in order to carry out complete exeresis of the damage. Also, revision of the literature emphasizing that today's therapeutical approach for RMS should essentially be multidisciplinary.

[Survival analysis in renal cell carcinoma with invasion of the vena cava]. / Análisis de la supervivencia en el carcioma de células renales con invasión de la vena cava.

Ninety-nine consecutive patients with renal cell carcinoma in stages pT1-4/N0-3/V0-2/M0 were analyzed. Overall 5 year survival was 61%. Factors with greater impact on survival were: 1) degree of anaplasia (DI 73%, DII 47%, DIII 27%; p = 0.0005), 2) pathological stage (pT1-2 87%, pT3 39%; p = 0.0000), 3) perirenal fat invasion (pT1-2 87%, pT3a 60%; p = 0.007), 4) node status (N0 72%, N1-3 17%; p = 0.0000) and 5) veins invasion (V0 74%, V1-2 35%; p = 0.005). No difference in survival between V1 and V2 (40% vs 33%; p0.05) tumours was found. A multivariable study showed that the degree of anaplasia and veins invasion have a significant and separate influence on survival (p = 0.0000). Among patients with vascular invasion, those with no perirenal fat invasion or node damage show better survival rates than patients with capsular infiltration (62% vs 40%; p) and perform significantly better than patients with capsular invasion and nodal implication (62% vs 30%; p). No survival differences were observed between pT3b stages with venous invasion only and pT1-2 stages (p0.05). Venous invasion is not in itself of prognostic relevance; the prognostic significance of vascular invasion is directly related to the presence of perirenal fat invasion and/or nodal implication.